Table 1.
Cannabinoid-based drugs.
| Cannabinoid Components | Brand Name | Origin | Indication(s) | Authorisation |
|---|---|---|---|---|
| Nabiximols (Δ9-THC and CBD 1:1) |
Sativex | Natural | Multiple sclerosis-related spasticity and neuropathic pain, and cancer-related pain | FDA/EMA |
| Nabilone (Δ9-THC analogue) |
Cesamet/Canemes | Synthetic | Chemotherapy-induced nausea and vomiting | FDA only |
| Dronabinol ((-)-trans-Δ9-THC) |
Marinol/Syndros | Synthetic | Anorexia related to AIDS, and nausea and vomiting induced by chemotherapy | FDA only |
| CBD | Epidyolex | Natural | Epilepsy | FDA/EMA |
| CBDV | GWP42006 | Natural | Rett syndrome, fragile X syndrome *, and autism ** | / |
| (Whole plant) | Cannabis FM2, Cannabis Flos, Pedanios |
Natural | Neuropathic and spasticity-associated pain, nausea and vomiting due to chemo/radiotherapy and HIV therapy, anorexia and cachexia, glaucoma, and Tourette syndrome | AIFA |
Δ9-THC = Δ9-tetrahydrocannabinol; CBD = cannabidiol; CBDV = cannabidivarin. * Received FDA/EMA orphan designation; ** ongoing trial.